drugset / Trial / NCT00002236

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

NCT00002236

Completed 32 enrolled Pharmacia and Upjohn
Open-labelTreatment

Summary

The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Delavirdine Small molecule
Subject INDINAVIR ANHYDROUS Other / unclassified
Subject Zidovudine Small molecule